StockData
Gelteq Ltd logo

Gelteq Ltd (GELS) shareholders

GELSNasdaqPharmaceutical PreparationsFiscal year ends June 30
Số liệu tài chính tới năm tài chính 2025, năm kết thúc ngày Jun 30, 2025Last filing: 20-F on Nov 16, 2026Score 0/30
$0.27−0.09 (-25.05%)

Close on Nov 17, 2026Market cap $2.88MP/E –Yield –

Ownership

Who owns Gelteq's shares

Held by institutions
–
Shares held, 13F filers
Institutional holders
–
Net institutional buying
–
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Paul Michael WYNNEChief Scientific Officer––Mar 18, 2026
Bradley Glenn KarpHead of Sales and Marketing500,0004.67%Mar 18, 2026
Nathan J. GivoniChief Executive Officer657,0876.13%Mar 18, 2026
Simon H. SzewachDirector338,1973.16%Mar 18, 2026

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of shares outstanding
–
0M shares short
Days to cover
2.1
At 0M shares a day
Change since last report
-27.5%
From 0M shares
Short volume, 20 days
32.3%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Gelteq's stock actually held short. Settlement fails (shares not delivered on time) peaked at 481,563 shares on Sep 4, 2026 over the last 90 days.

See a number that looks wrong?